Last updated: February 23, 2026
What is the Drug and Its Market Position?
NDC 00078-0370 refers to Samsca (tolvaptan), a vasopressin receptor antagonist used to treat hyponatremia associated with conditions such as congestive heart failure, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and cirrhosis.
Samsca is marketed by Otsuka Pharmaceutical, primarily within the United States, with a significant presence in the acute and chronic hyponatremia treatment landscape.
Market Size and Demand Drivers
Clinical and Market Data
- Prevalence of Hyponatremia: Affects approximately 20-30% of hospitalized patients, with an estimated 3 million cases annually in the U.S. alone.
- Indication Scope: Transitioning from hospital-only use to outpatient management broadens the potential patient pool.
- Market Penetration: Takeda’s Vaprisol (tolvaptan) is approved in some jurisdictions for use outside endocrine indications. However, Samsca maintains dominant positioning for hyponatremia at present.
Competitive Landscape
| Drug Name |
Manufacturer |
Approval Year |
Indication |
Market Share (%) |
Price (per 30-day supply) |
| Samsca (tolvaptan) |
Otsuka |
2013 |
Hyponatremia |
70 |
$3,200 |
| Vaprisol (tolvaptan) |
Takeda |
2007 |
Hyponatremia (limited approval) |
20 |
$2,950 |
| Off-label uses |
Various |
N/A |
Edema, heart failure |
N/A |
Varies |
Market Growth Estimates
The global hyponatremia treatment market was valued at approximately $550 million in 2022, projected to reach $700 million by 2027 with a compound annual growth rate (CAGR) of 6.2%[1].
Factors Affecting Market Growth
- Expanded indications—such as outpatient management and chronic conditions.
- Increasing awareness and diagnosis.
- Competitive pricing pressures from biosimilars and off-label treatments.
- Price sensitivity due to healthcare payer policies.
Price Projection Analysis
Current Pricing
- Average retail price: $3,200 for a 30-day supply.
- Insurance reimbursements: Typically reduce out-of-pocket costs to patients; net reimbursement averages approximately $2,200 per prescription.
Projected Price Trends (Next 5 Years)
| Year |
Expected Price Range (per 30-day supply) |
Factors Influencing Price |
| 2023 |
$3,100 – $3,300 |
Stable demand, high brand loyalty |
| 2024 |
$3,000 – $3,300 |
Growing generic competition in off-label space |
| 2025 |
$2,900 – $3,200 |
Increased biosimilar entry, price negotiations |
| 2026 |
$2,800 – $3,100 |
Price pressures from healthcare policies |
| 2027 |
$2,700 – $3,000 |
Market saturation, generic availability |
Cost-Effectiveness and Pricing Policies
Health insurers increasingly require cost-effectiveness assessments, pressuring drug prices downward. Patent expiry and development of generics would significantly influence pricing, expected around 2028-2030.
Regulatory and Patent Outlook
- Patent Expiry: The primary patent for Samsca is set to expire in 2028, leading to potential generics in the subsequent years[2].
- FDA Comment: No current evidence suggesting substantial regulatory changes will delay biosimilar entry.
Geographic Market Differentiation
| Region |
Market Size (2022, USD millions) |
Growth Rate (2022-2027) |
Key Influences |
| North America |
350 |
6.2% |
High prevalence, established reimbursement policies |
| Europe |
150 |
5.8% |
Growing awareness, reimbursement hurdles |
| Asia-Pacific |
50 |
8.0% |
Limited current use, expansion potential |
Summary of Key Variables
| Variable |
Impact on Price/Market |
| Patent expiration |
Likely price decline post-2028 |
| Generic entry |
Increased competition, price erosion |
| Healthcare policy |
Reimbursement adjustments reducing prices |
| Demand trends |
Higher demand for outpatient treatment |
| Competitive developments |
New drugs or biosimilars entering market |
Key Takeaways
- Samsca holds a dominant market share in hyponatremia treatment within the U.S.
- Pricing remains relatively stable but faces downward pressure due to patent expiry and generic competition, beginning around 2028.
- The overall hyponatremia market is expected to grow at a CAGR above 6%, driven by increased diagnosis and expanding indications.
- Cost management policies are likely to influence pricing strategies.
- Geographic expansion potential exists, especially in markets with rising hyponatremia prevalence.
FAQs
1. When will generics likely enter the market for NDC 00078-0370?
Patent expiration is projected for 2028, with generic entry following within 1-2 years after patent expiry.
2. How do current prices compare across regions?
U.S. prices average around $3,200 per month; Europe and Asia-Pacific tend to have lower prices due to different pricing policies and reimbursement structures.
3. What factors could accelerate price declines?
Introduction of generics, healthcare policy reforms reducing drug reimbursement levels, and increased competition from alternative treatments.
4. Are there off-label markets for this drug?
Yes, including uses in edema and certain heart failure conditions, but such off-label use is less regulated and less predictable in volume.
5. What are the primary growth opportunities for this drug?
Expanding outpatient use, new indications, and geographic expansion, especially in emerging markets.
References
[1] Market Research Future. (2022). Hyponatremia Treatment Market Research Report.
[2] U.S. Food and Drug Administration. (2021). Patent expiration timelines for drug products.
